Home Special Topics Technology Offerings Content

Inhalative administration of fibrinogen IIb/IIIa receptor antagonists for prompt acute therapy in the event of thrombus formatio

next article

13.12.2006

The effect of the intravenously administered fibrinogen IIb/IIIa receptor antagonist Tirofiban as a thrombocyte aggregation inhibitor is known and well investigated. Now, for the first time, the dispersal of Tirofiban in the form of an aerosol has been achieved, which allows application of the produced aerosol via inhalation. This has the advantage that the active ingredients are reabsorbed very quickly after deposition and rapidly reach a therapeutically active drug level in the blood, which leads to life-saving thrombocyte aggregation inhibition. With this the possibility for acute and immediate treatment of diseases which are caused by or in conjunction with thrombus formation is finally available.

Further Information: PDF

TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12

Contact
Dr. Peter Stumpf

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

info@technologieallianz.de | Source: TechnologieAllianz e.V.
Further information: www.technologieallianz.de/angebote.php?sort=sag&id=0888&lang=en
www.technologieallianz.de

next article